ACHV compared with ALLO: revenue, margins and what each company keeps, and the suppliers and customers both name

ACHVAchieve Life Sciences, Inc.

Mkt capRevenueRevenue

ALLOAllogene Therapeutics, Inc.

Mkt capRevenueRevenue

Compare

ACHVAchieve Life Sciences, Inc.

ALLOAllogene Therapeutics, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

ACHV1 of 4 reports

0 of 1at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±10.9%▼−1.18%×0.11

ALLO

0 of 4at or beyond implied

Reportimpliedrealized× implied

Q3 FY26±25.3%▼−4.59%×0.18

Q2 FY26±13.3%▼−4.35%×0.32

= impliedACHV realized, solidALLO realized, hatchedOne scale, both sides: full bar = 34%× = |realized| ÷ impliedSource: market data

May 14 '26

±14.0%

▼−8.15%

×0.59

Q1 FY26±33.1%▼−2.83%×0.08

ACHVAchieve Life Sciences, Inc.

6.71▲+5.33%· post 6.71

Mkt cap$691.5MRevenue—

ALLOAllogene Therapeutics, Inc.

1.04▼−4.59%· post 1.07

ClosedNov 6 '26

Mkt cap$360.3MRevenue$5MQ2 FY26

Compare

ClosedNov 6 '26

ACHVAchieve Life Sciences, Inc.

ALLOAllogene Therapeutics, Inc.

6.71▲+5.33%post 6.71

Price

1.04▼−4.59%post 1.07

$691.5M

Mkt cap

$360.3M

—

Revenue

$5MQ2 FY26

ACHV6.71▲+5.33%vsALLO1.04▼−4.59%ClosedNov 6 '26